Major Depressive Disorder Clinical Trials in New York, New York
33 recruitingNew York, New York
Showing 1–20 of 33 trials
Recruiting
Not Applicable
Maintenance rTMS for Depression (Maitr-De)
Major Depressive DisorderTreatment Resistant Depression
University of California, San Diego75 enrolled3 locationsNCT06938841
Recruiting
Phase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences850 enrolled87 locationsNCT06966401
Recruiting
Phase 2
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Major Depressive Disorder
Syndeio Biosciences, Inc164 enrolled32 locationsNCT07115329
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled42 locationsNCT07076407
Recruiting
Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Sirtsei Pharmaceuticals, Inc.456 enrolled50 locationsNCT06254612
Recruiting
Not Applicable
Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality
DepressionDepressive DisorderSuicidal Ideation+1 more
Weill Medical College of Cornell University128 enrolled1 locationNCT05925322
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled45 locationsNCT07065240
Recruiting
Phase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Major Depressive Disorder
AbbVie195 enrolled31 locationsNCT07276997
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Major Depressive Disorder (MDD)
Vanda Pharmaceuticals500 enrolled38 locationsNCT06830044
Recruiting
Not Applicable
DBS for TRD With the Medtronic Percept PC
Major Depressive DisorderTreatment Resistant Depression
Helen Mayberg, MD10 enrolled1 locationNCT05773755
Recruiting
Phase 2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Major Depressive Disorder
Autobahn Therapeutics, Inc.230 enrolled50 locationsNCT06633016
Recruiting
Phase 2
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
Major Depressive Disorder
NYU Langone Health16 enrolled1 locationNCT05757791
Recruiting
Not Applicable
Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
DepressionMajor Depressive DisorderMajor Depressive Episode+1 more
NYU Langone Health40 enrolled1 locationNCT07111390
Recruiting
Not Applicable
Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression
Major Depressive Disorder
Icahn School of Medicine at Mount Sinai80 enrolled1 locationNCT05933148
Recruiting
Phase 2
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
Major Depressive Disorder
Icahn School of Medicine at Mount Sinai70 enrolled1 locationNCT06559826
Recruiting
Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Intra-Cellular Therapies, Inc.470 enrolled60 locationsNCT05850689
Recruiting
Phase 4
Aβ Dynamics in LLMD
Alzheimer DiseaseMajor Depressive Disorder
NYU Langone Health60 enrolled2 locationsNCT05004987
Recruiting
Phase 2
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
Major Depressive Disorder
Icahn School of Medicine at Mount Sinai60 enrolled1 locationNCT06592833
Recruiting
Phase 4
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Major Depressive Disorder
Axsome Therapeutics, Inc.350 enrolled40 locationsNCT06223880